Ico Institut Catala D Oncologia

Barcelona 08908

1 studies enrolling now · 5 studies all time

What they study most

Bladder Carcinoma, Chronic Lymphocytic Leukemia, Cutaneous Melanoma, Endometrial Carcinoma, Epithelial Ovarian Carcinoma, Esophageal Carcinoma, Fallopian Tube Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Carcinoma, Invasive Breast Carcinoma, Lymphoma, Metastatic Urothelial Carcinoma

Studies at this site

• ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation — Recruiting now
• A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) — Stopped early
• INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma — Stopped early
• Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) — Stopped early
• A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) — Completed